

Peer-reviewed publications written with the investigators

My name can be found in the acknowledgements, in accordance with ICMJE requirements.

1. [Gyurkocza](#) B, et al. (2024) Randomized phase III SIERRA trial of ¹³¹I-apamistamab before allogeneic hematopoietic cell transplantation vs conventional care for relapsed/refractory acute myeloid leukemia. *J Clin Oncol* 2024 doi: 10.1200/JCO.23.02018.
2. [Finn](#) RS, et al. (2024) Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150. *Liver Cancer* 1-14.
3. [Yamamoto](#) N, et al. (2024) Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers. *J Immunother Cancer* 12
4. [Muangnoicharoen](#) S, et al. (2024) Heterologous Ad26.COVID.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial. *Vaccine* 42:3999-4010.
5. [Divan](#) HE, et al. (2024) Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer. *BMC Cancer* 24:424.
6. [Bamias](#) A, et al. (2023) Atezolizumab monotherapy versus chemotherapy in untreated metastatic urothelial carcinoma: final overall survival analysis from the randomised, phase III IMvigor130 study. *Lancet Oncol* 25:46-61.
7. [Bosch](#) F, et al. (2023) Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma. *Clin Lymphoma Myeloma Leuk* 24:105-121.
8. [Muangnoicharoen](#) S, et al. (2023) Single Ad26.COVID.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: day 28 results of a phase 1/2 open-label trial. *Vaccine* 41:4648-4657.
9. [Stieh](#) DJ, et al. (2023) Safety and immunogenicity of Ad26-vectored HIV vaccine with mosaic immunogens and a novel mosaic envelope protein in HIV-Uninfected adults: a phase 1/2a study. *J Infect Dis.* 227: 939-950.
10. [Felip](#) E, et al. (2023) Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. *Ann Oncol* 34:907-919.
11. [Rudin](#) CM, et al. (2023) Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. *ESMO Open* 8:101160.
12. [Ko](#) AH, et al. (2023) Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib/II umbrella randomized study platform. *Oncologist* doi: 10.1093/oncolo/oyad022.
13. [Nishimura](#) JI, et al. (2023) Mitigating drug-target-drug complexes in patients with paroxysmal nocturnal hemoglobinuria who switch C5 inhibitors. *Clin Pharmacol Ther* doi: 10.1002/cpt.2851.
14. [Cheng](#) AL, et al. (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol* 76:862-73.
15. [Fu](#) S, et al. (2022) Phase 1b study of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. *J Clin Oncol* 40:2568-2577.
16. [Tabernero](#) J, et al. (2022) Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. *ESMO Open* 7:100419. doi: 10.1016/j.esmoop.2022.100419.
17. [Saqi](#) A, et al. (2022) Assessing pathologic response in resected lung cancers: current standards, proposal for a novel pathologic response calculator tool, and challenges in practice. *JTO Clin Res Rep* 3:100310. doi: 10.1016/j.jtocrr.2022.100310.
18. [Lee](#) JM, et al (2022) Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer. *Ann Thor Surg* S0003-4975(21)01300-X.

19. [Felip E](#), et al. (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. *Lancet* doi: 10.1016/S0140-6736(21)02098-5.
20. [Lee JM](#), et al. (2021) Important surgical and clinical end points in neoadjuvant immunotherapy trials in resectable NSCLC. *JTO Clin Res Rep* 2(10).
21. [Galle P](#), et al. (2021) Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): a phase 3 randomised trial. *Lancet Oncol* 22:991-1001.
22. [Qin S](#), et al. (2021) Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. *Liver Cancer* doi: 10.1159/000513486.
23. [Ardizzoni A](#), et al. (2021) Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. *J Immunother Cancer* doi: 10.1136/jitc-2020-001865.
24. [Moroney JW](#), et al. (2020) Safety and clinical activity of atezolizumab plus bevacizumab in patients with ovarian cancer: a phase Ib study. *Clin Can Res* doi: 10.1158/1078-0432.CCR-20-0477.
25. [Finn RS](#), et al. (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med* 382:1894-1905.
26. [Powell DR](#), et al. (2019) Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. *J Clin Endocrinol Metab* doi: 10.1210/clinem/dgz258.
27. [Ma F](#), et al. (2019) Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. *J Clin Oncol* 37:2610-2619.
28. [Li J](#), et al. (2018) Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESKO randomized clinical trial. *JAMA* 319:2486-2496.
29. [Lu S](#), et al. (2018) Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol* 36:1207-1217.
30. [Kapoor KM](#), et al. (2017) Consensus recommendations for treatment strategies in Indians using botulinum toxin and hyaluronic acid fillers. *Plast Reconstr Surg Glob Open* 5:e1574. doi: 10.1097/GOX.0000000000001574.
31. [Sáez-Llorens X](#), et al. (2017) Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. *Lancet Infect Dis* 17:615-625.
32. [Sirivichayakul C](#), et al. (2016) Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study. *J Infect Dis* 213:1562-1572.
33. [Wu W](#), et al. (2016) Consensus on current injectable treatment strategies in the Asian face. *Aesth Plast Surg* 40:202-214.
34. [Osorio JE](#), et al. (2016) A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. *Expert Rev Vaccines* 15:497-508.
35. [Liew S](#), et al. (2016) Consensus on changing trends, attitudes, and concepts of Asian beauty. *Aesth Plast Surg* 40:193-201.
36. [Lee JH](#), et al. (2016) Consensus on optimal nutrition therapy in the paediatric critical care environment in Asia-Pacific and the Middle East. *Asia Pac J Clin Nutr* doi: 10.6133/apjcn.
37. [Rupp R](#), et al. (2015) Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study. *Vaccine* 33:6351-6359.
38. [Wong JG](#), et al. (2015) Identifying adult dengue patients at low risk for clinically significant bleeding. *PLoS One* 11:e0148579.

39. [Xu W](#), et al. (2015) Comparison of the effects on glycaemic control and B-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). *J Int Med* 277;137-150.
40. [Qi S](#), et al. (2013) Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. *J Clin Oncol* 31:3501-3508.
41. [Capeding MR](#), et al. (2013) Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children. *PloS One Negl Trop Dis* 7:e2331.
42. [Ji L](#), et al. (2013) Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. *PLoS One* 8:e57222.
43. [Huang KE](#) & [Baber R](#). (2010) Updated clinical recommendations for the use of tibolone in Asian women. *Climacteric*. 13(4):317-327.
44. [Chow SN](#), et al. (2010) Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. *Vaccine* 28:3809-3817.
45. [Basu P](#), et al. (2009) HPV vaccination in women over 25 years of age: Asian Cervical Cancer Prevention Advisory Board recommendations. *J Obstet Gynaecol Res* 35:712-6.